RS66530B1 - Metode lečenja fabrijeve bolesti kod pacijenata koji imaju mutaciju u gla genu - Google Patents

Metode lečenja fabrijeve bolesti kod pacijenata koji imaju mutaciju u gla genu

Info

Publication number
RS66530B1
RS66530B1 RS20250171A RSP20250171A RS66530B1 RS 66530 B1 RS66530 B1 RS 66530B1 RS 20250171 A RS20250171 A RS 20250171A RS P20250171 A RSP20250171 A RS P20250171A RS 66530 B1 RS66530 B1 RS 66530B1
Authority
RS
Serbia
Prior art keywords
mutation
migalastat
patient
gal
seq
Prior art date
Application number
RS20250171A
Other languages
English (en)
Serbian (sr)
Inventor
Elfrida Benjamin
Xiaoyang Wu
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75267607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS66530(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of RS66530B1 publication Critical patent/RS66530B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RS20250171A 2020-03-06 2021-03-05 Metode lečenja fabrijeve bolesti kod pacijenata koji imaju mutaciju u gla genu RS66530B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062986297P 2020-03-06 2020-03-06
PCT/US2021/020984 WO2021178737A1 (en) 2020-03-06 2021-03-05 Methods of treating fabry disease in patients having a mutation in the gla gene
EP21715035.8A EP4114390B1 (en) 2020-03-06 2021-03-05 Methods of treating fabry disease in patients having a mutation in the gla gene

Publications (1)

Publication Number Publication Date
RS66530B1 true RS66530B1 (sr) 2025-03-31

Family

ID=75267607

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20250171A RS66530B1 (sr) 2020-03-06 2021-03-05 Metode lečenja fabrijeve bolesti kod pacijenata koji imaju mutaciju u gla genu

Country Status (25)

Country Link
US (1) US20230136297A1 (cg-RX-API-DMAC7.html)
EP (2) EP4527454A3 (cg-RX-API-DMAC7.html)
JP (2) JP7749572B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220152547A (cg-RX-API-DMAC7.html)
CN (1) CN115427040A (cg-RX-API-DMAC7.html)
AR (1) AR122390A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021230371A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017881A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170718A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002423A1 (cg-RX-API-DMAC7.html)
DK (1) DK4114390T3 (cg-RX-API-DMAC7.html)
ES (1) ES3013813T3 (cg-RX-API-DMAC7.html)
FI (1) FI4114390T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250179T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070116T2 (cg-RX-API-DMAC7.html)
IL (1) IL296221A (cg-RX-API-DMAC7.html)
LT (1) LT4114390T (cg-RX-API-DMAC7.html)
MX (1) MX2022011030A (cg-RX-API-DMAC7.html)
PL (1) PL4114390T3 (cg-RX-API-DMAC7.html)
PT (1) PT4114390T (cg-RX-API-DMAC7.html)
RS (1) RS66530B1 (cg-RX-API-DMAC7.html)
SI (1) SI4114390T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500072T1 (cg-RX-API-DMAC7.html)
TW (1) TW202146020A (cg-RX-API-DMAC7.html)
WO (1) WO2021178737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3840753T (lt) * 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
WO2009102895A2 (en) * 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2012125402A2 (en) * 2011-03-11 2012-09-20 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
US11034946B2 (en) * 2017-10-05 2021-06-15 Research Foundation Of The City University Of New York Glycosylation independent proteins

Also Published As

Publication number Publication date
HUE070116T2 (hu) 2025-05-28
PL4114390T3 (pl) 2025-06-23
TW202146020A (zh) 2021-12-16
ES3013813T3 (en) 2025-04-15
SI4114390T1 (sl) 2025-03-31
LT4114390T (lt) 2025-02-10
HRP20250179T1 (hr) 2025-04-11
EP4527454A2 (en) 2025-03-26
US20230136297A1 (en) 2023-05-04
AU2021230371A1 (en) 2022-09-29
JP2026016375A (ja) 2026-02-03
AR122390A1 (es) 2022-09-07
EP4114390B1 (en) 2024-12-04
SMT202500072T1 (it) 2025-03-12
EP4114390A1 (en) 2023-01-11
DK4114390T3 (da) 2025-02-24
CN115427040A (zh) 2022-12-02
JP7749572B2 (ja) 2025-10-06
KR20220152547A (ko) 2022-11-16
PT4114390T (pt) 2025-02-24
FI4114390T3 (fi) 2025-03-07
MX2022011030A (es) 2022-12-13
CL2022002423A1 (es) 2023-05-05
EP4527454A3 (en) 2025-09-24
WO2021178737A1 (en) 2021-09-10
BR112022017881A2 (pt) 2022-12-06
JP2023516753A (ja) 2023-04-20
IL296221A (en) 2022-11-01
CA3170718A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
US20240277687A1 (en) Methods of treating fabry disease in patients having a mutation in the gla gene
RS66515B1 (sr) Metode unapređenja i/ili stabilizacije srčanih funkcija kod pacijenata sa fabrijevom bolešću
RS67913B1 (sr) Postupci lečenja fabrijeve bolesti
EP4114390B1 (en) Methods of treating fabry disease in patients having a mutation in the gla gene
RS66410B1 (sr) Upotreba migalostata u smanjenju rizika od cerebrovaskularnog događaja kod pacijenata sa fabrijevom bolešću
RS67478B1 (sr) Dozni režim migalastata sa poboljšanom farmakokinetikom
RS66376B1 (sr) Lečenje fabri pacijenata koji imaju određene mutacije
HK40104441A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40122460A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104069A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104071A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104764A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40105450A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40057125B (en) Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene
HK40057125A (en) Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene